Join
Live feed
·
PRReleasevia Quantisnow
Capricor Therapeutics Inc. logo

Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

ByQuantisnow·Wall Street's wire, on your screen.
CAPR· Capricor Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CAPR (Capricor Therapeutics Inc.) and more on Quantisnow.